Peter Max
- CEO Partner
Transaction Description
Gemstone Capital acted as financial advisor in Brain+’s IPO (Initial Public offering). The IPO was concluded with a total subscription percentage of 169%. Therefore, Brain+ received gross proceeds of DKK 15 million and converted all debt from the pre-IPO funding as described in the Company Description. Of the maximum IPO amount, 50.1% or DKK 7.5 million was pre-subscribed. This means that a total of DKK 7.5 million was offered for open public subscription.
Contact Person
Company Description
Brain+ is a pioneer in developing medical software to treat the cognitive symptoms of dementia, and the most common cause of dementia, namely Alzheimer’s disease. Together with world-leading experts and institutions, the Company digitize the best-in-class, non-drug dementia therapies, and make them broadly available on standard digital devices – for use both in people’s homes and at healthcare clinics. This approach is referred to as Digital Therapeutics or Digital Medicine.
Financial and strategic advisors
to high caliber growth companies
in pursuit of market leadership.
© 2025 Gemstone Capital – Designet af Aveo webmarketing